This was launched in December 2005 and the MHRA isworking with the Commission on Human Medicines’ Patient Information ExpertAdvisory Group to discuss how this leaflet and the patient Yellow Card can befurther promoted and made available. The MHRA is also developing acommunication campaign, which includes articles in magazines, and working withvoluntary organisations to promote patient reporting of suspected adversereactions.